Singapore, February 9, 2023 – Detection of the latest SARS-CoV-2 Variant Strain
In response to the rise of new Covid-19 variants, Credo Diagnostics Biomedical Pte Ltd continues to ensure the effectiveness of our assays using BLASTn analysis. (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID from September 1st, 2022 to January 31st, 2023.
We are pleased to announce that our VitaPCR™ system is capable of detecting the Omicron XBB.1.5 subvariant, and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariant, XBB.1.5.
*The SARS-CoV-2 RNA detection assays include:
． VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
． VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
． VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
For more information, contact us at service@credodxbiomed.com.
